Virologic versus cytologic triage of women with equivocal pap smears: A meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

Journal of the National Cancer Institute

Volumn 96, Issue 4, 2004, Pages 280-293

  Arbyn, Marc ^a   Buntinx, Franx ^b,c   van Ranst, Marc ^b   Paraskevaidis, Evangelos ^d   Martin Hirsch, Pierre ^e   Dillner, Joakim ^f  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^e LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSAY; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; DNA DETERMINATION; FEMALE; HUMAN; HUMAN TISSUE; META ANALYSIS; PAPANICOLAOU TEST; PRIORITY JOURNAL; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STANDARDIZATION; STATISTICAL MODEL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

EID: 1342312269     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh037     Document Type: Article

References (95)

1. Franco EL, Rohan TE, editors. Cancer precursors. Epidemiology, detection and prevention. New York (NY): Springer-Verlag; 2002. p. 1-430.
2. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9.
3. Cox JT. HPV testing: is it useful in triage of minor Pap abnormalities? J Fam Pract 1998;46:121-4.
4. Robertson JH, Woodend BE, Crozier EH, Hutchinson J. Risk of cervical cancer associated with mild dyskaryosis. BMJ 1988;297:18-21.
5. Coleman D, Day N, Douglas G, Farmery E, Lynge E, Philip J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Europe against cancer programme. Eur J Cancer 1993;29A Suppl 4:S1-38.
6. Flannelly G, Anderson D, Kitchener HC, Mann EM, Campbell M, Fisher P, et al. Management of women with mild and moderate cervical dyskaryosis. BMJ 1994;308:1399-403.
7. Arbyn M, Albertyn G, De Groof V. Consensus on follow-up recommendations in cervical cancer screening (in Dutch). Tijdschr voor Geneeskunde 1996;52:709-15.
8. Noumoff JS. Atypia in cervical cytology as a risk factor for intraepithelial neoplasia. Am J Obstet Gynecol 1987;156:628-31.
9. Richart RM. Causes and management of cervical intraepithelial neoplasia. Cancer 1987;60(8 Suppl):1951-9.
10. Richart RM, Wright TC Jr. Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 1993;71(4 Suppl):1413-21.
11. Soutter WP. Management of women with mild dyskaryosis. Immediate referral to colposcopy is safer. BMJ 1994;309:591-2.
12. Ferenczy A. Viral testing for genital human papillomavirus infections: recent progress and clinical potentials. Int J Gynecol Cancer 1995;5:321-8.
13. Wilkinson C, Jones JM, McBride J. Anxiety caused by abnormal result of cervical smear test: a controlled trial. BMJ 1990;300:440.
14. Narod SA, Thompson DW, Jain M, Wall C, Green LM, Miller AB. Dysplasia and the natural history of cervical cancer: early results of the Toronto Cohort Study. Eur J Cancer 1991;27:1411-6.
15. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-92.
16. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;92:727-35.
17. Murdoch JB, Grimshaw RN, Morgan PR, Monaghan JM. The impact of loop diathermy on management of early invasive cervical cancer. Int J Gynecol Cancer 1992;2:129-33.
18. Cox JT, Lorincz AT, Schiffman MH, Sherman ME, Cullen A, Kurman RJ. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 1995;172:946-54.
19. Wright TC, Sun XW, Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 1995;85:202-10.
20. Kinney WK, Manos MM, Hurley LB, Ransley JE. Where's the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998;91:973-6.
21. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994;186:131-56.
22. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
23. Munoz N. Human papilloma virus and cervical cancer: epidemiological evidence. In: Franco E, Monsonego J, editors. New developments in cervical cancer screening and prevention. Oxford (UK): Blackwell Science; 1997. p. 3-13.
24. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
25. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.
26. Kaufman RH, Adam E. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities? Gynecol Oncol 1998;70:317-8.
27. Kaufman RH, Adam E. Is human papillomavirus testing of value in clinical practice? Am J Obstet Gynecol 1999;180:1049-53.
28. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, et al. A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Technol Assess 1999;3:i-iv, 1-196.
29. Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract 1998;46:125-34.
30. Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998; 46:136-41.
31. Morin C, Bairati I, Bouchard C, Fortier M, Roy M, Moore L, et al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. J Reprod Med 2001;46:799-805.
32. Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
33. Sherman ME, Schiffman M, Cox JT; Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002;94:102-7.
34. Arbyn M, Buntinx F, Van Ranst M, Cortiñas Abrahantes J. Triage of women with atypical or low-grade cytological abnormalities of the cervix by HPV testing: systematic review and meta-analysis. Brussels (Belgium): Institute of Public Health/Epidemiology Reports No. 2001-019[D/2001/2505/34]. 2002. p. 1-244.
35. Luff RD. The Bethesda System for reporting cervica)/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. The Bethesda System Editorial Committee. Hum Pathol 1992;23:719-21.
36. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu 1973;8:301-28.
37. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94.
38. Light RJ, Singer JD, Willet JB. The visual presentation and interpretation of meta-analysis. In: Cooper H, editor. The handbook of research synthesis. New York (NY): Russell Sage Foundation; 1994. p. 439-54.
39. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester (UK): John Wiley & Sons, Ltd.; 2000. p. 1-317.
40. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29.
41. Dersimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
42. Sharp S, Sterne J. Meta-analysis. Stata Technical Bulletin 1997;38:9-14
43. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96:410-6.
44. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
45. Steichen TJ. Tests for publication bias in meta-analysis. Stata Technical Bulletin 1998;7:125-33.
46. Goff BA, Muntz HG, Bell DA, Wertheim I, Rice LW. Human papillomavirus typing in patients with Papanicolaou smears showing squamous atypia. Gynecol Oncol 1993;48:384-8.
47. Slawson DC, Bennett JH, Simon LJ, Herman JM. Should all women with cervical atypia be referred for colposcopy: a HARNET study. Harrisburgh Area Research Network. J Fam Pract 1994;38:387-92.
48. Fait G, Daniel Y, Kupferminc MJ, Lessing JB, Niv J, Bar-Am A. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities? Gynecol Oncol 1998;70:319-22.
49. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281:1605-10.
50. Bergeron C, Jeannel D, Poveda J, Cassonnet P, Orth G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000;95:821-7.
51. Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB, et al. Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral. Gynecol Oncol 2000;79:177-80.
52. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS. High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age. J Reprod Med 2000;45:345-50.
53. Rebello G, Hallam N, Smart G, Farquharson D, McCafferty J. Human papillomavirus testing and the management of women with mildly abnormal cervical smears: an observational study. BMJ 2001;322:893-4.
54. Zielinski DG, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, et al. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. J Pathol 2001;195:300-6.
55. Cox JT, Schiffman MH, Winzelberg AJ, Patterson JM. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol 1992;80:389-95.
56. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-5; discussion 1155-7.
57. Herrington CS, Evans ME, Hallam NF, Charnock FM, Gray W, McGee JD. Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities. Br J Cancer 1995;71:206-9.
58. Ferenczy A, Franco E, Arseneau J, Wright TC, Richart RM. Diagnostic performance of Hybrid Capture human papillomavirus deoxyribonucleic acid assay combined with liquid-based cytologic study. Am J Obstet Gynecol 1996;175:651-6.
59. Hall S, Lorincz A, Shah F, Sherman ME, Abbas F, Paull G, et al. Human papillomavirus DNA detection in cervical specimens by hybrid capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol 1996;62:353-9.
60. Bollen LJ, Tjong-A-Hung SP, Van der Velden J, Brouwer K, Mol BW, ten Kate FJ, et al. Human papillomavirus deoxyribonucleic acid detection in mildly or moderately dysplastic smears: a possible method for selecting patients for colposcopy. Am J Obstet Gynecol 1997;177:548-53.
61. Kaufman RH, Adam E, Icenogle J, Reeves WC. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness. Am J Obstet Gynecol 1997;177:930-6.
62. Kaufman RH, Adam E, Icenogle J, Lawson H, Lee N, Reeves KO, et al. Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1997;176:87-92.
63. Adam E, Kaufman RH, Berkova Z, Icenogle J, Reeves WC. Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? Am J Obstet Gynecol 1998;178:1235-44.
64. Nyirjesy I, Billingsley FS, Forman MR. Evaluation of atypical and low-grade cervical cytology in private practice. Obstet Gynecol 1998;92:601-7.
65. Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, et al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group. CMAJ 2000;163:701-7.
66. Mould TA, Singer A, Gallivan S. Quantitative detection of oncogenic HPV DNA using hybrid capture to triage borderline and mildly dyskaryotic Papanicolaou smears. Eur J Gynaecol Oncol 2000;21:245-8.
67. Lorincz AT. Methods of DNA hybridisation and their clinical applicability to human papillomavirus detection. In: Franco E, Monsonego J, editors. New developments in cervical cancer screening and prevention. Oxford (UK): Blackwell Science; 1997. p. 325-37.
68. O'Sullivan JP, Ismail SM, Barnes WS, Deery AR, Gradwell E, Harvey JA, et al. Interobserver variation in the diagnosis and grading of dyskaryosis in cervical smears: specialist cytopathologists compared with non-specialists. J Clin Pathol 1994;47:515-8.
69. Sherman ME, Schiffman MH, Lorincz AT, Manos MM, Scott DR, Kuman RJ, et al. Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol 1994;102:182-7.
70. Gatscha RM, Abadi M, Babore S, Chhieng D, Miller MJ, Saigo PE. Smears diagnosed as ASCUS: interobserver variation and follow-up. Diagn Cytopathol 2001;25:138-40.
71. Stoler MH, Schiffman M; Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
72. Castle PE, Lorincz AT, Mielzynska-Lohnas I, Scott DR, Glass AG, Sherman ME, et al. Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol 2002;40:1088-90.
73. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
74. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000;44:726-42.
75. Boyko EJ. Re: "Meta-analysis of Pap test accuracy". Am J Epidemiol 1996;143:406-7.
76. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 2002;287:2382-90.
77. Wright TC Jr, Lorincz A, Ferris DG, Richart RM, Ferenczy A, Mielzynska I, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998; 178:962-6.
78. Morrison SA. Screening in chronic disease. In: Kelsey JL, Marmot MG, Stolley PD, Vessey MP, editors. Series Monogr Epidemiol Biostat. Vol 19. 2nd ed. Oxford (UK): Oxford University Press; 1992. p. 1-254.
79. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31:14-9.
80. Sherman ME, Wang SS, Tarone R, Rich L, Schiffman M. Histopathologic extent of cervical intraepithelial neoplasia 3 lesions in the atypical squamous cells of undetermined significance low-grade squamous intraepithelial lesion triage study: implications for subject safety and lead-time bias. Cancer Epidemiol Biomarkers Prev 2003;12:372-9.
81. ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1393-92.
82. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses. National Cancer Institute Workshop. JAMA 1989;262:931-4.
83. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
84. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ; ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
85. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA 2002;287:2140-1.
86. Sherman ME, Tabbara SO, Scott DR, Kurman RJ, Glass AG, Manos MM, et al. "ASCUS, rule out HSIL": cytologic features, histologic correlates, and human papillomavirus detection. Mod Pathol 1999;12:335-42.
87. Sherman ME, Solomon D, Schiffman M; ASCUS LSIL Triage Study Group. Qualification of ASCUS. A comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study. Am J Clin Pathol 2001;116:386-94.
88. Quddus MR, Sung CJ, Steinhoff MM, Lauchlan SC, Singer DB, Hutchinson ML. Atypical squamous metaplastic cells: reproducibility, outcome, and diagnostic features on ThinPrep Pap test. Cancer 2001;93:16-22.
89. Quddus MR, Zhang S, Sung CJ, Liu F, Neves T, Struminsky J, et al. Utility of HPV DNA detection in thin-layer, liquid-based tests with atypical squamous metaplasia. Acta Cytol 2002;46:808-12.
90. Hughes SA, Sun D, Gibson C, Bellerose B, Rushing L, Chen H, et al. Managing atypical squamous cells of undetermined significance (ASCUS): human papillomavirus testing, ASCUS subtyping, or follow-up cytology? Am J Obstet Gynecol 2002;186:396-403.
91. Scott DR, Hagmar B, Maddox P, Hjerpe A, Dillner J, Cuzick J, et al. Use of human papillomavirus DNA testing to compare equivocal cervical cytologic interpretations in the United States, Scandinavia, and the United Kingdom. Cancer 2002;96:14-20.
92. Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES). Management of a patient with an abnormal cervical smear. Service Recommandations et Références Professionnelles et Service Evaluation Economique. Paris (France): ANAES; 2002. p. 1-92.
93. Medical Services Advisory Committee (MSAC). Human papillomavirus testing in women with cytological prediction of low-grade abnormality. MSAC reference 12b, Canberra (Australia): 2003. p. 1-97.
94. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. J Natl Cancer Inst 2000;92:397-402.
95. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400.